Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs Novavax Inc (NVAX) Price & Performance

Airbnb, Inc.Trade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Airbnb, Inc. vs Novavax Inc — how do they compare? Airbnb, Inc. trades at $180.9 (market cap $110.76B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Airbnb, Inc. is far larger — about 84.5× Novavax Inc's market cap, and Airbnb, Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

ABNBNVAX
Market Cap
$110.76B$1.31B
Sector
Consumer CyclicalHealth
52-Week High
$184.98$11.19
52-Week Low
$111.54$6.22
Enterprise Value
$101.19B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

ABNB trades at $180.06, down 2.51% today but remains near recent highs following strong Q2 2026 earnings that beat expectations. The stock shows bullish technical momentum with moving averages supporting upward trends, though oscillators indicate potential overbought conditions. Fundamentally, Airbnb demonstrates robust revenue growth with $12.24B in 2025 revenue and impressive 82.9% gross margins, though valuation multiples remain elevated with a P/E of 42.23. Recent news highlights the company's strategic pivot toward AI integration and expansion into hotel listings and travel services.

The outlook remains positive with analyst consensus leaning toward Buy (46.7% of ratings) and a $173.26 price target, though current price exceeds this consensus. Key opportunities include AI-driven efficiency gains and travel demand recovery, while risks involve premium valuation sensitivity and competitive pressures in the evolving travel marketplace. Institutional sentiment appears cautiously optimistic given recent earnings momentum.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX